Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

EXTON, Pa., March 22, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced data presented in two poster presentations relating to Cinryze® (C1 esterase inhibitor [human]) at the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, March 18 through 22, in San Francisco, CA.  

Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease.  Cinryze is currently available only in the United States, and is not approved in the U.S. to treat acute angioedema attacks, for children with HAE, or for pre-procedure administration.

"As leaders in hereditary angioedema medical education, we continue to expand the body of data available on Cinryze usage," commented David Mariano, PharmD, ViroPharma's director of medical communications. "Our goal is to leverage educational initiatives to reinforce the understanding and awareness of HAE and its management for physicians and other healthcare professionals who may care for patients suffering from HAE."

AAAAI Poster Presentations

In a poster entitled, 'Pre-procedural Administration of Nanofiltered C1 Esterase Inhibitor (Human) (Cinryze®) for the Prevention of Hereditary Angioedema (HAE) Attacks after Medical, Dental, or Surgical Procedures,' Dr. William Lumry, M.D., of the University of Texas Southwestern Medical School in Dallas, Texas discussed the potential for Cinryze to prevent attacks of HAE that are triggered by trauma such as dental work, elective medical procedures and surgery.  Data compiled from all completed studies with Cinryze were presented on the experience of 41 subjects who received Cinryze prior to 91 procedures.  Cinryze 1000U
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Germany , July 30, 2014  invendo ... and computer-assisted ("robotic") colonoscopy system, today announced the appointment ... medical device executive, as a new member of its ... highly respected global visionary in the medical device industry. ... and Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
(Date:7/31/2014)... Pass, OR (PRWEB) July 31, 2014 Sales ... 12-percent from 2013 to 2014, according to radio talk show ... has been experiencing rapid growth since 1990. The US economy ... Sharon Kleyne Hour Power of Water radio show, reported this ... Bragg Live Foods, a worldwide manufacturer of organic and natural ...
(Date:7/31/2014)... According to new research report ... by Type (Tofu, Tofu-Based Product, Tempeh, TVP, Seitan, ... Trends & Forecasts to 2019", defines and segments ... and forecasting of the market value of sources, ... also identifies the driving and restraining factors for ...
(Date:7/31/2014)... July 31, 2014 Care Communications, Inc., ... outsourcing firm, has received the Elite Award for “Recruitment, ... Resources, one of twelve elite awards presented as part ... to Work For” 2014 awards competition. This marks ... Elite Award in the competition. CARE has also been ...
(Date:7/31/2014)... July 31, 2014 Daily Gossip reveals in ... help sufferers discover some breakthrough weight loss tips. , ... tips and recommendations are very simple to implement. Users don’t ... foods, with no need to start counting calories. , ... who in fact created a 12 weeks weight loss program ...
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
Breaking Medicine News(10 mins):Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2
... century, John Snow mapped cases of cholera in Soho, London, ... water pump. Now, in a twenty-first century equivalent, scientists funded ... the latest in gene sequencing technology and global positioning system ... trace its source. Typhoid fever is caused by two ...
... Updated guidelines from the American Academy of Pediatrics (AAP) ... (ADHD) in younger children and in adolescents. Emerging ... in children from ages 4 to 18 (the previous ... 6 to 12). The new guidelines describe the special ...
... , SATURDAY, Oct. 15 (HealthDay News) -- Head injuries are ... a new study finds. Researchers examined data on 52 ... at a pediatric trauma center between 2003 and 2011. The ... 10 and the most common cause of injury was hitting ...
... BOSTON - An in-hospital delay of appendicitis treatment ... likelihood of complications, including perforation and abscess formation; ... according an abstract presented Saturday, Oct. 15 at ... and Exhibition in Boston. In "Missed Opportunities ...
... 14 (HealthDay News) -- Flu activity levels in the United ... get a flu shot, the U.S. Centers for Disease Control ... for the 2011-2012 flu season, the federal agency also said ... the U.S. supply is projected to be at an all-time ...
... One in six people in the United States is affected ... multiple sclerosis, and more research is required to find new ... mark its 20th anniversary, the foundation has released a video ... ongoing research. "Brain disease is in the news every ...
Cached Medicine News:Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 2Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 3Health News:AAP expands ages for diagnosis and treatment of ADHD in children 2Health News:Delayed pediatric appendicitis treatment linked to complications, and even death 2Health News:Get Your Flu Shot Now, CDC Urges 2Health News:Foundation Aims to Raise Awareness of Brain Diseases 2
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
... ToolBox is an advanced medical ... Emergency, Pediatric Dosing and Critical ... is a logical complement to ... as the Daviss Drug Guide, ...
... the handheld version of ... drug interaction analyzer covering ... generic drugs. iFacts™ enables ... to accurate and reliable ...
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
Medicine Products: